EF Hutton Acquisition Corp I

Issuing above the 19.99% cap at a price below the Nasdaq Minimum Price is the most dilutive form of approval a company can seek - it means shares are being sold below market to the financing counterparties, so existing holders are diluted on both count and price. Three separate instruments dated across July, August and September 2025 show successive rounds of the same financing. The Series C 5% dividend adds a continuing claim ahead of common.

Authority to execute multiple reverse splits up to a cumulative 1-for-200 over a full year is close to unlimited discretion over the share count, and it is paired with approval to issue stock under two separate financing agreements signed two weeks apart. ECD would return in December 2025 seeking to issue above the 19.99% cap at below the Nasdaq Minimum Price, so this meeting begins a continuous dilution cycle against $21.1 million of principal debt.

The deadline is stated and short. Stockholders approved on June 1, 2023 an extension of up to nine one-month steps from June 13, 2023 to March 13, 2024, each funded by depositing into the trust account the lesser of $80,000 and $0.04 for each public share, and the filing says EFHAC has extended only to November 13, 2023. At that June 2023 vote 8,007,353 shares were tendered for redemption, leaving 3,492,647 public shares. Assuming no further redemptions, EFHAC's stockholders keep about 14.6% of the combined company against 74.5% for the ECD Securityholders.

The preferred stock in which part of the consideration is denominated does not exist yet at this version — the cover calls it EFHAC's to be designated Series A Convertible Preferred Stock, so its terms are not before the holders being asked to vote. The clock is explicit: an extension approved on June 1, 2023 runs up to nine one-month steps from June 13, 2023 to March 13, 2024, each funded by depositing the lesser of $80,000 and $0.04 per public share, and EFHAC has extended only to November 13, 2023. At that June vote 8,007,353 shares were redeemed, leaving 3,492,647 public shares.

The trust has already been drained once: at the June 1, 2023 extension vote 8,007,353 shares were tendered for redemption, leaving 3,492,647 public shares, and EFHAC has extended two months to August 13, 2023 on monthly deposits of the lesser of $80,000 and $0.04 per public share, extendable up to nine times to March 13, 2024. Assuming no further redemptions the public keeps approximately 16.9% against 72.2% for the ECD Securityholders and 10.9% for the Initial Stockholders; at maximum redemptions the public falls to about 12.3% while the Initial Stockholders rise to 11.5%.

The trust has already been drained: at the extension vote on June 1, 2023, 8,007,353 shares were tendered for redemption, leaving 3,492,647 public shares outstanding, and the charter was amended to allow up to nine one-month extensions from June 13, 2023 to March 13, 2024, funded by depositing the lesser of $80,000 and $0.04 per public share each month. Assuming none of the remaining shares redeem, EFHAC's public stockholders keep about 15.1% of the combined company against 64.4% for ECD's securityholders; at maximum redemptions those become 13.5% and 65.6%.